What will the FDA's decision be on Zidesamtinib by Nuvalent in 2026?
Markets
Every market on this event, moneyline first. Select one to compare it across platforms in the side panel.
| Outcome | Best | Azuro | Gemini | Kalshi | Limitless | Novig | Polymarket | Polymarket US |
|---|---|---|---|---|---|---|---|---|
Yes Winner | 99.0%Kalshi | — | — | — | — | — | — | |
No | 1.0%Kalshi | — | — | — | — | — | — |
Description from Kalshi. A cross-platform summary is generated once this event is matched across platforms.
If the FDA's decision on Zidesamtinib by Nuvalent in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Zidesamtinib (also known by its development code NVL-520) is an experimental cancer medicine made by Nuvalent Inc. that is designed to fight a specific type of lung cancer driven by a faulty molecular switch called ROS1. Think of ROS1 as a car's accelerator pedal stuck in the "floored" position — it keeps cancer cells growing uncontrollably — and zidesamtinib acts like a clamp that holds the pedal back, slowing or stopping that runaway growth. It is a small-molecule drug, meaning it is taken as a pill and can travel throughout the body, including into the brain, where ROS1-driven lung cancers commonly spread.
Discussion (0)
Log in to join the discussion.
No comments yet — start the discussion.